Darbepoetin alfa

Janessa Smith, Pharm.D., BCPS, Paul A. Pham, Pharm.D.

INDICATIONS

FDA

  • Anemia due to chronic kidney disease (CKD) in patients on dialysis and those not on dialysis
  • Anemia due to myelosuppressive chemotherapy with a minimum of at least 2 months of planned therapy

NON-FDA APPROVED USES

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: December 4, 2016